BP230- and BP180-specific Auto-Antibodies in Bullous Pemphigoid-Reference-Cited by-同舟云学术

BP230- and BP180-specific Auto-Antibodies in Bullous Pemphigoid

Published:2004-06 Issue:6 Volume:122 Page:1413-1422
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Thoma-Uszynski Sybille,Uter Wolfgang,Schwietzke Susanne,Hofmann Silke C.,Hunziker Thomas,Bernard Philippe,Treudler Regina,Zouboulis Christos C.,Schuler Gerold,Borradori Luca,Hertl Michael

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference43 articles.

1. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus;Amagai;J Clin Invest,1994

2. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain;Balding;J Invest Dermatol,1996

3. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: Evidence that BP180 spans the lamina lucida;Bedane;J Invest Dermatol,1997

4. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid;Bernard;Clin Immunol Immunopathol,1990

5. The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the beta4 integrin subunit;Borradori;J Cell Biol,1997

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diacron-Reactive Oxygen Metabolites Levels Are Initially Elevated in Patients with Bullous Pemphigoid;JID Innovations;2024-07

2. Immunobullous Diseases;Rook's Textbook of Dermatology;2024-03-19

3. Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches;Clinical Reviews in Allergy & Immunology;2023-10-28

4. Immune cells in pemphigus vulgaris and bullous Pemphigoid: From pathogenic roles to targeting therapies;International Immunopharmacology;2023-10

5. Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid;Skin Research and Technology;2023-10